Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
1. Intellia reports positive 24-month data for nexiguran ziclumeran in ATTRv-PN. 2. 92% TTR reduction observed in patients receiving higher doses after 24 months. 3. 72% of patients showed clinically meaningful improvements in neuropathy scores. 4. Nex-z demonstrated good tolerability with mild side effects; no treatment discontinuations. 5. BLA submission for nex-z anticipated by 2028, with patient screening ongoing.